U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07434843) titled 'PH 2 Pemigatinib in SDH-deficient GIST' on Dec. 29, 2025.
Brief Summary: The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability.
The name of the study drug involved in this study is:
* Pemigatinib (INCB054828)
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
SDH Gene Mutation
Gastrointestinal Stromal Tumor
Intervention:
DRUG: Pemigatinib
A selective Fibroblast Growth F...